Rapid reversal of haematoma expansion associated with vitamin K antagonists

The Lancet Neurology

Volumn 15, Issue 6, 2016, Pages 535-537

  Eikelboom, John W ^a,b   Bosch, Jacqueline ^a   Hart, Robert G ^a  

^a HAMILTON HEALTH SCIENCES   (Canada)

^b NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDEXANET ALFA; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; FRESH FROZEN PLASMA; HEMOSTATIC AGENT; IDARUCIZUMAB; PROTHROMBIN; PROTHROMBIN COMPLEX; RIVAROXABAN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; VITAMIN K GROUP;

ANTICOAGULANT THERAPY; BRAIN FUNCTION; BRAIN HEMATOMA; BRAIN HEMORRHAGE; HEMOSTASIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; NOTE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; HEMATOMA;

ANTICOAGULANTS; BLOOD COAGULATION FACTORS; HEMATOMA; HUMANS; INTERNATIONAL NORMALIZED RATIO; VITAMIN K;

EID: 84962920561     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(16)30008-4     Document Type: Note

References (14)

1. Aguilar MI, Hart RG, Kase CS, et al. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc 2007, 82:82-92.
2. Rosand J, Eckman MH, Knudsen KA, et al. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004, 164:880-884.
3. Steiner T, Poli S, Griebe M, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol 2016, 15:566-573.
4. Sarode R, Milling TJ, Refaai MA, et al. Efficacy and safety of a four-factor prothrombin complex concentrate (4F-PCC) in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 2013, 128:1234-1243.
5. Goldstein JN, Refaai MA, Milling TJ, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet 2015, 385:2077-2087.
6. Flibotte JJ, Hagan N, O'Donnell J, Greenberg SM, Rosand J Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 2004, 63:1059-1064.
7. Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation related intracerebral hemorrhage. JAMA 2015, 313:824-836.
8. Hart RG, Tonarelli SB, Pearce LA Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke 2005, 36:1588-1593.
9. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet 2013, 382:507-515. THE SPS3 Study Group.
10. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001, 358:1033-1041. PROGRESS Collaborative Group.
11. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014, 383:955-962.
12. Pollack CV, Reilly PA, Eikelboom J, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015, 373:511-520.
13. Eikelboom JW, Quinlan DJ, van Ryn J, Weitz JI Idarucizumab: the antidote for reversal of dabigatran. Circulation 2015, 132:2412-2422.
14. Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015, 373:2413-2424.